# Time‐Dependent Predictive Accuracy Metrics in the Context of Interval Censoring and Competing Risks

## TL;DR

This paper introduces two methods to evaluate prediction models for time-to-event outcomes in the presence of interval censoring and competing risks.

## Contribution

The study proposes a model-based and IPCW approach for time-dependent accuracy metrics in interval-censored competing risk settings.

## Key findings

- The model-based approach uses all subjects in the risk set for accuracy evaluation.
- The IPCW approach focuses only on subjects with known event status in the interval of interest.
- Both methods were tested using simulations and a prostate cancer surveillance cohort.

## Abstract

Evaluating the performance of a prediction model is a common task in medical statistics. Standard accuracy metrics require the observation of the true outcomes. This is typically not possible in the setting with time‐to‐event outcomes due to censoring. Interval censoring, the presence of time‐varying covariates, and competing risks present additional challenges in obtaining those accuracy metrics. In this study, we propose two methods to deal with interval censoring in a time‐varying competing risk setting: a model‐based approach and the inverse probability of censoring weighting (IPCW) approach, focusing on three key time‐dependent metrics: area under the receiver‐operating characteristic curve, Brier score, and expected predictive cross‐entropy. The evaluation is conducted over a medically relevant time interval of interest, [t,Δt). The model‐based approach includes all subjects in the risk set, using their predicted risks to contribute to the accuracy metrics. In contrast, the IPCW approach only considers the subset of subjects who are known to be event‐free or experience the event within the interval of interest. We performed a simulation study to compare the performance of the two approaches with regard to the three metrics. Furthermore, we demonstrated the three metrics using the two approaches on an example prostate cancer surveillance cohort. Risk predictions were generated from a joint model handling the interval‐censored cancer progression and the competing event, early treatment, and repeatedly measured biomarkers.